We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Next Generation Digital PCR System Launched

By LabMedica International staff writers
Posted on 01 May 2012
The innovative system is designed for advanced performance standards in sensitivity, multiplexing, and absolute quantitation in polymerase chain reaction (PCR) analysis.

The system is capable of generating more than a billion reactions in a single day, and transforms the performance of molecular assays by enabling digital answers across a number of important applications.

The technology is based on patented and proven RainStorm picodroplet technology; the RainDrop System generates up to 10 million picoliter-sized droplets per lane. More...
Since each droplet encapsulates a single molecule, scientists can quickly determine the absolute number of droplets containing specific target DNA and compare that to the number of droplets with background wild-type DNA.

The RainDrop System (RainDance Technologies; Lexington MA, USA) also shifts the current digital PCR (dPCR) paradigm from a single-color-per-marker approach to a two color and varying probe intensity method that is capable of multiplexing up to 10 markers. It will be particularly useful for the detection low-frequency tumor allele, gene expression, copy number variation, and single-nucleotide polymorphism (SNP) measurement.

French scientists from the Université de Strasbourg (France) used the RainDance dPCR technology to detect a single mutated copy of the Kirsten rat sarcoma viral oncogene homolog (KRAS) in a background of 200,000 wild-type copies. By processing reactions in millions of picoliter droplets, the platform improved sensitivity by two orders of magnitude compared to existing technologies. Beginning in the summer of 2012, RainDance will be offering a select number of scientists the opportunity to participate in the RainDrop First Access Program. The wet-lab sessions will provide hands-on instrumentation and software training with assays and samples. Participants will also be able to choose from a fixed menu of assays and run up to 32 of their own samples.

Pierre Laurent-Puig, MD, PhD, of the Université Paris Descartes (France) said, "With RainDance digital PCR, we were able to achieve absolute quantification of mutated and tumor-circulating DNA and improve the detection of a circulating tumor by comparing its proportion to nontumor DNA. Absolute quantification is critical, especially in studies that lays the groundwork for future clinical applications, because it allows you to generate meaningful thresholds that will be required for prognostic and diagnostic tools.”

Related Links:
RainDance Technologies
Université de Strasbourg
Université Paris Descartes


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.